Curium announced today that it opened a new facility in Petten, The Netherlands, to produce non-carrier added lutetium-177 (Lu-177). The Paris-based company expanded its capacity to meet the growing global demand for Lu-177 for the treatment of cancer patients. Using in-licensed technology from Turkey-based Eczacıbaşı-Monrol, the facility will initially include two production lines. Curium also…